Guangzhou Innogen Pharmaceutical (HKG:2591) said its H shares have been added to both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Monday, according to a same-day bourse filing.
The inclusion will allow mainland investors to trade the company's H shares through the Shanghai and Shenzhen stock exchanges.
The board said the move is expected to broaden the firm's investor base, boost liquidity, and strengthen its profile in the capital market.